STOCK TITAN

GSK plc American Depositary Shares (Each representing two Ordinary Shares) - GSK STOCK NEWS

Welcome to our dedicated page for GSK plc American Depositary Shares (Each representing two Ordinary Shares) news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK plc American Depositary Shares (Each representing two Ordinary Shares) stock.

GSK plc (formerly known as GlaxoSmithKline plc) is a leading British multinational pharmaceutical and biotechnology company headquartered in London, England. It ranks among the largest pharmaceutical companies globally by total sales, marking its influence in the industry. GSK’s core business segments include prescription medicines, vaccines, and consumer healthcare products. The company has a strong presence in therapeutic areas such as respiratory, oncology, antiviral treatments, and vaccines.

GSK leverages innovations in science and technology to develop and deliver a range of new treatments. Recent achievements include significant advancements in the development of respiratory therapies and cancer treatments. The company also focuses on combating infectious diseases through its strong vaccine portfolio, which includes vaccines for diseases like shingles, influenza, and hepatitis.

Financially, GSK demonstrates robust performance with consistent revenue growth driven by its diverse product pipeline and strategic market presence. The company engages in joint ventures to expand its reach, notably in the HIV market through its collaboration with ViiV Healthcare.

GSK’s commitment to improving global health is evidenced by its dynamic research and development efforts, strategic partnerships, and innovative product launches. Recent news highlights the company’s collaboration with Elegen and Elsie Biotechnologies, Inc., signifying its ongoing efforts to enhance its product offerings and research capabilities.

Investors and stakeholders can stay informed about GSK’s developments and performance by following the latest company news, financial updates, and product announcements.

Rhea-AI Summary
GSK announces that AREXVY, a vaccine for Respiratory Syncytial Virus (RSV), is now available in major retail pharmacies in the US. The vaccine is recommended for individuals aged 60 and older to prevent RSV-lower respiratory tract disease. Medicare Part D patients will have no out-of-pocket expenses, and commercially insured patients may have coverage at no cost when administered in-network.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.78%
Tags
-
Rhea-AI Summary
LimmaTech Biologics has signed an in-license agreement with GlaxoSmithKline Biologicals to develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis. The vaccine is being tested in a Phase I/II study, with results expected in 2023. Shigellosis causes 600,000 deaths annually and there is an urgent need for a vaccine. LimmaTech Bio is an independently owned Swiss biotech company that spun out from GlycoVaxyn after its acquisition by GSK in 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary
GSK has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2023-24 flu season. The company expects to distribute over 40 million doses of its influenza vaccine to the US market. The vaccines are available in a 0.5mL, single-dose, pre-filled syringe and are recommended for patients six months and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
Rhea-AI Summary
BELLUS Health Inc. announces positive outcome of shareholder vote on acquisition by GSK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none

FAQ

What is the current stock price of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)?

The current stock price of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is $33.35 as of November 15, 2024.

What is the market cap of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)?

The market cap of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is approximately 68.0B.

What is GSK plc?

GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, England, known for its prescription medicines, vaccines, and consumer healthcare products.

What are the main therapeutic areas GSK focuses on?

GSK focuses on respiratory diseases, oncology, antiviral treatments, and vaccines.

What recent collaborations has GSK engaged in?

Recent collaborations include partnerships with Elegen and Elsie Biotechnologies, Inc.

How does GSK expand its reach in the HIV market?

GSK expands its reach in the HIV market through its joint venture with ViiV Healthcare.

Where is the headquarters of GSK located?

GSK’s headquarters are located in London, England.

What achievements has GSK made recently?

GSK has made significant advancements in respiratory therapies, cancer treatments, and vaccine development.

What is the financial condition of GSK?

GSK demonstrates robust financial performance with consistent revenue growth driven by a diverse product pipeline and strategic market presence.

How can investors stay updated about GSK?

Investors can stay updated by following the latest company news, financial updates, and product announcements.

What does GSK's product portfolio include?

GSK's product portfolio includes prescription medicines, vaccines for various diseases, and consumer healthcare products.

Does GSK engage in research and development?

Yes, GSK is committed to improving global health through dynamic research and development efforts.

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

NYSE:GSK

GSK Rankings

GSK Stock Data

67.97B
4.15B
0.06%
15.46%
0.81%
Drug Manufacturers - General
Healthcare
Link
United States of America
Brentford